
|Articles|April 1, 2004
Phase II study shows oral tazarotene treatment yields QOL benefits for sufferers of severe acne
Washington D.C. ?? Patients with severe nodulocystic acne treated with oral tazarotene experience a substantial improvement in acne-specific health-related quality of life (HRQOL), according to the results of a Phase II dose-ranging study presented by Patricia S. Walker, M.D., Ph.D., at the annual meeting of the American Academy of Dermatology.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
2
Moving Past Dermal Filler Trends to Focus on Healthy Skin Aging
3
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
4
Filling the HS Treatment Gap: Ruxolitinib Targets Early-Stage Disease
5














